Domainex Ltd

Domainex whose first project will be out-licensed in 2013 and will generate value over next 3 years by trade sale or sale of projects.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Cambridge, England, GB
  • Currency GBP
  • Founded January 2001
  • Employees 35
  • Website domainex.co.uk

Company Summary

Domainex has two business units. A service business that generates revenues and a drug discovery unit that has programmes around kinases for oncology and epigenetics. Domainex's pipeline is unique in focussing upon challenging and novel targets which is now reaching a stage were we anticipate a first out-licensing deal which will generate value for the company during 2013.

Team

  • Eddy Littler
    Dr

    Eddy has worked in senior roles for 23 years in Pharma and Biotech with Wellcome, GSK and Medivir. In his time at Medivir he played a major role in the development and out-licensing of a hepatitis C drug to J&J.
    At Domainex he has raised over £3m from angel and corporate investors and has led the company to generate over £15m in revenues.

  • Trevor Perrior
    Dr

    Trevor has spent over 20 years in pharma and biotech with ICI, Astrazeneca and Celltech. He has taken 10 drugs into the clinic with one marketed drug

  • Eddy Littler

Advisors

  • Charles Waddell
    Lawyer
    Unconfirmed
    Anthony Signorini
    Accountant
    Unconfirmed

Previous Investors

  • Longbow Capital, Bury Fitzwilliam-Lay, UCLB, Takeda Ventures
    Unconfirmed
    Capital Fund, BBSF
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free